Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081266 | 1.00 | RPS6KB1 (0.51) | RPS6KB1SYKMAPK14ROCK2ROCK1 | |
| SCHEMBL7082077 | 0.88 | SYK (0.52) | RPS6KB1SYKMAPK14ROCK2ROCK1 | |
| SCHEMBL5409200 | 0.82 | RPS6KB1 (0.52) | RPS6KB1SYKMAPK14ROCK2ROCK1 | |
| SCHEMBL5409202 | 0.82 | RPS6KB1 (0.52) | RPS6KB1SYKMAPK14ROCK2ROCK1 | |
| SCHEMBL7078494 | 0.80 | ROCK2 (0.53) | RPS6KB1SYKROCK2ROCK1 | |
| SCHEMBL7081258 | 0.80 | ROCK2 (0.53) | SYKROCK2ROCK1 | |
| SCHEMBL7077421 | 0.76 | ROCK2 (0.55) | SYKROCK2ROCK1 | |
| SCHEMBL7079063 | 0.76 | ROCK2 (0.55) | ROCK2ROCK1POLB | |
| SCHEMBL5415168 | 0.76 | MAPK14 (0.67) | RPS6KB1MAPK14ROCK2ROCK1 | |
| SCHEMBL5415165 | 0.76 | MAPK14 (0.67) | RPS6KB1MAPK14ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608058-B2 | Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome | DONG WHA PHARM. IND. CO., LTD. (KR) | 2003-08-19 | — | — | US | claimed |
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | DONG WHA PHARM. CO., LTD. (KR) | 2003-05-15 | — | — | US | claimed |
| US-6608058-B2 | Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome | DONG WHA PHARM. IND. CO., LTD. (KR) | 2003-08-19 | — | — | US | disclosed |
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | DONG WHA PHARM. CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | TPMT, HAVCR2, NNMT | RPS6KB1 645/4885SYK 4369/4885MAPK14 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.